← Human Trials & Peer-Reviewed Studies
Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial
Plain-language guide to PMID 24739875 (2014): randomized controlled trial study of Insulin Detemir and NPH Insulin (isophane) in 32 patients.
Key Facts
- PMID
- 24739875
- Journal
- PloS one
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- van Golen LW et al. (8 authors)
- DOI
- 10.1371/journal.pone.0094483
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Detemir and NPH Insulin (isophane), published as a randomized controlled trial.
The aim of this study was to investigate whether insulin detemir treatment differentially modifies brain activation in response to food stimuli as compared to NPH insulin.
Why It Was Studied
In humans, these effects are less well established.
Insulin detemir is a basal insulin analog that causes less weight gain than other basal insulin formulations, including the current standard intermediate-long acting Neutral Protamine Hagedorn (NPH) insulin.
Who Took Part
The study group was 32 patients.
In addition, cerebral spinal fluid (CSF) insulin levels were measured after both treatments.
Brain responses to viewing food and non-food pictures were measured using functional Magnetic Resonance Imaging in 32 type 1 diabetic patients, after each of two 12-week treatment periods with insulin detemir and NPH insulin, respectively, both combined with prandial insulin aspart.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Insulin Detemir and who got the comparison, which limits bias.
What Was Measured
CSF insulin levels were determined in a subgroup.
The subject headings attached to it are Appetite Regulation, Blood-Brain Barrier, Brain Mapping, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin and Insulin Detemir.
What This Means in Plain Language
The paper is a randomized study of Insulin Detemir and NPH Insulin (isophane) in 32 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2014 (PloS one), a journal based in United States.
More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page, all human trials.
Our Notes on the Compounds
Insulin Detemir: A long-acting basal insulin analog sold as Levemir.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.